Rufinamide for the treatment of Lennox–Gastaut syndrome

Bibliography

• Arzimanoglou A, French J, Blume WT, Lennox–Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology [Review]. Lancet Neurol 2009;8:82-93
   PubMed Web of Science ®Google Scholar
• Dulac O, Engel J. Lennox–Gastaut Syndrome. 2003. Available from: http://www.ilae-epilepsy.org/visitors/centre/ctf/lennox_gastaut.html [Last accessed 11 December 2010]
   Google Scholar
• Kieffer-Renaux V, Kaminska A, Dulac O. Cognitive deterioration in Lennox–Gastaut and Doose epilepsy. In: Jambaque I, Lassonde M, Dulac O, editors, Neuropsychology of childhood epilepsy. Kluwer Academic/Plenum Publishers, New York; 2001. p. 185-90
   Google Scholar
• Deekollu D, Besag FM, Aylett SE. Seizure-related injuries in a group of young people with epilepsy wearing protective helmets: incidence, types and circumstances. Seizure 2005;14:347-53
   PubMed Web of Science ®Google Scholar
• Besag FM. Behavioural effects of the newer antiepileptic drugs: an update [Review]. Expert Opin Drug Saf 2004;3:1-8
   PubMedGoogle Scholar
• Besag FM. Behavioral aspects of pediatric epilepsy syndromes [Review]. Epilepsy Behav 2004;5(Suppl 1):S3-13
   PubMed Web of Science ®Google Scholar
• Motte J, Trevathan E, Arvidsson JF, Lamotrigine for generalized seizures associated with the Lennox–Gastaut syndrome. Lamictal Lennox–Gastaut Study Group. N Engl J Med 1997;337:1807-12, Published erratum appears in N Engl J Med 1998;339:851-2
   PubMed Web of Science ®Google Scholar
• Sachdeo RC, Glauser TA, Ritter F, A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome. Topiramate YL study group. Neurology 1999;52:1882-7
   PubMed Web of Science ®Google Scholar
• Efficacy of felbamate in childhood epileptic encephalopathy (Lennox–Gastaut syndrome). The felbamate study group in lennox–gastaut syndrome. N Engl J Med 1993;328:29-33
   PubMed Web of Science ®Google Scholar
• Schmidt D, Kramer G. The new anticonvulsant drugs. Implications for avoidance of adverse effects [Review]. Drug Saf 1994;11:422-31
   PubMed Web of Science ®Google Scholar
• Felbamate linked to aplastic anemia; warning issued on drug's use. Am J Hosp Pharm 1994;51:2324
   PubMedGoogle Scholar
• You SJ, Kang HC, Ko TS, Comparison of corpus callosotomy and vagus nerve stimulation in children with Lennox–Gastaut syndrome. Brain Dev 2008;30:195-9
   PubMed Web of Science ®Google Scholar
• Frost M, Gates J, Helmers SL, Vagus nerve stimulation in children with refractory seizures associated with Lennox–Gastaut syndrome. Epilepsia 2001;42:1148-52
   PubMed Web of Science ®Google Scholar
• Freeman JM. The ketogenic diet: additional information from a crossover study. J Child Neurol 2009;24:509-12
   PubMed Web of Science ®Google Scholar
• Conry JA, Ng YT, Paolicchi JM, Clobazam in the treatment of Lennox–Gastaut syndrome. Epilepsia 2009;50:1158-66
   PubMed Web of Science ®Google Scholar
• Sheth RD, Goulden KJ, Ronen GM. Aggression in children treated with clobazam for epilepsy. Clinical Neuropharmacology 1994;17(4):332-7
   PubMed Web of Science ®Google Scholar
• Sheth RD, Goulden KJ, Ronen GM. Aggression in children treated with clobazam for epilepsy. Clin Neuropharmacol 1994;17:332-7
   PubMed Web of Science ®Google Scholar
• Inovelon Summary of Product Characteristics. 2009 Dec 15. Available from: http://www.medicines.org.uk/emc/medicine/20165/SPC/ [Last accessed 12 December 2010]
   Google Scholar
• Eisai, Inc. Banzel (rufinamide) prescribing information. 2011. Available from: http://www.eisai.com/package_inserts/Banzel_PI pdf [Last accessed 29 January 2011]
   Google Scholar
• Elger CE, Stefan H, Mann A, A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res 2010;88:255-63
   PubMed Web of Science ®Google Scholar
• Kluger G, Kurlemann G, Haberlandt E, Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav 2009;14:491-5
   PubMed Web of Science ®Google Scholar
• Kluger G, Haberlandt E, Kurlemann G, First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav 2010;17:546-8
   PubMed Web of Science ®Google Scholar
• Glauser T, Kluger G, Sachdeo R, Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome. Neurology 2008;70:1950-8
   PubMed Web of Science ®Google Scholar
• Vendrame M, Loddenkemper T, Gooty VD, Experience with rufinamide in a pediatric population: a single center's experience. Pediatric Neurol 2010;43:155-8
   PubMed Web of Science ®Google Scholar
• Olsen HE, Loddenkemper T, Vendrame M, Rufinamide for the treatment of epileptic spasms. Epilepsy Behav 2011;1-5, doi:10.1016/j.yebeh.2010.11.023
   Web of Science ®Google Scholar
• Gallop K, Wild D, Nixon A, Impact of Lennox–Gastaut Syndrome (LGS) on health-related quality of life (HRQL) of patients and caregivers: literature review [Review]. Seizure 2009;18:554-8
   PubMed Web of Science ®Google Scholar
• Verdian L, Yi Y. Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox–Gastaut Syndrome in the United Kingdom. Seizure 2010;19:1-11
   PubMed Web of Science ®Google Scholar